The Catalyst

Most Recent Posts

04.09.14 | By Robert J. Hugin

The guest post below by Robert Hugin originally appeard on The Hill. Hugin is the chairman and CEO of Celgene Corporation and chairman of PhRMA

America's status as the research lab for the world is no longer secure.


Day one of #PhRMA14 was a success! Celgene CEO and PhRMA Chairman Bob Hugin set the tone for the meeting by emphasizing the industry’s commitment to the patient. It is because of that commitment that we have seen tremendous progress and a real prospect of producing dramatic breakthroughs. Yet, there are still challenges that must be addressed, and discussions tomorrow will speak to six key initiatives to help address them.


After many months of planning and hard work, I’m excited for the kick-off of PhRMA’s 2014 Annual Meeting tomorrow afternoon at 4pm. I think we have a great meeting planned – and I’m thrilled to announce that nearly all of it will be live-streamed on our website.

04.07.14 | By Stephanie Fischer

Biopharmaceutical innovation is not a given.  Strong intellectual property protections are necessary to sustain America’s role as the worldwide leader in biopharmaceutical research and are critical to the biopharmaceutical industry’s ability to make the

04.01.14 | By Gabriela Lavezzari

This month, the Institute of Medicine released a summary of a workshop I participated in that addressed the critical role of collaboration within the biopharmaceutical industry. As part of this program, academia, providers, industry professionals, patient advocates and government regulators shared their perspectives.


Another year of innovative research and development (R&D) to help patients around the world live longer, healthier lives has flown by. Beginning April 9, leaders from the biopharmaceutical industry, patient advocates, regulators, academics and others will gather in Washington, D.C. for this year’s PhRMA Annual Meeting.


This month, a New York Times editorial discussed the cost of a new drug to treat hepatitis C. The opinion piece took a short-term view of treating the disease, noting that a panel of experts concluded that the drug offered “low value” for treating most patients, in large part due to its cost.


Helen Keller once said, “Alone we can do so little; together we can do so much.”While all members of the biopharmaceutical industry are working toward the common goal of improving patient health, it is through collaboration that we have seen diseases eradicated and innovative treatments emerge from the pipeline. This week, we highlight some of the collaborative efforts currently underway to help patients across the world. 


This week’s Medicines in Development report for Parkinson’s disease examines the work currently underway to help the 1.5 million Americans who are affected by the progressive neurological condition. While high-profile Parkinson’s patients like Michael J.

Dr. Salvatore Alesci, PhRMA Vice President
03.26.14 | By Jon Tripp

The magnificent architecture of the South Carolina State House served as the backdrop for Diabetes under the Dome – an event obviously focusing on one of the state’s worst health nightmares: diabetes.

03.26.14 | By Stephanie Fischer

While the number of patients with any individual rare disease is relatively small, they collectively affect 1 in 10 Americans. The community successfully comes together to raise awareness on international Rare Disease Day every February, but the challenge is how to maintain the momentum – and remain united - for the remaining 364 days of the year.

03.20.14 | By John Castellani

In January, the Centers for Medicaid and Medicare Services (CMS) issued a proposed rule that would have adversely altered Medicare Part D’s six protected classes for prescription medication, restricting Medicare beneficiary access to antidepressants and immunosuppressants beginning in 2015.

03.19.14 | By Stephanie Fischer

The development of new medical breakthroughs depends on the patients who volunteer to participate in clinical trials, but according to the Center for Information and Study on Clinical Research Participation, only 6 percent of clinical trials are completed on time and half of clinical research sites enroll one or no patients in their study.


This week we focused on the role of patients within the R&D process, from discovery to market access.


You could have heard a pin drop as onetime clinical trial participant Laura Hull spoke at yesterday's "Research in Your Backyard" event in Winston-Salem, N.C. More than a few eyes had tears in them.